For research use only. Not for use in humans.

Sirukumab (Anti-IL-6 / IFNb2)

Synonyms: IL-6, BSF-2

Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD.

Sirukumab (Anti-IL-6 / IFNb2)

Quality Control

Batch: A298001 Purity: 99% Protein concentration: 5.32mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD.
References

Product Details

CAS No. 1194585-53-9
Molecular Weight 144.58
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05305066 RECRUITING Drug: TNFi|Drug: Anti-IL6|Drug: JAKi Rheumatoid Arthritis Marie Hudson, MD 2023-02-01
NCT05679570 COMPLETED Drug: Satralizumab (Genetical Recombination) Pulmonary Arterial Hypertension International University of Health and Welfare 2022-07-12 PHASE2
NCT03380962 ACTIVE_NOT_RECRUITING Drug: Clazakizumab Kidney Failure, Chronic; End-Stage Renal Disease; Transplant Glomerulopathy; Transplant;Failure,Kidney; Kidney Transplant Failure and Rejection; Antibody-mediated Rejection; Kidney Transplant; Complications Stanley Jordan, MD 2018-02-27 PHASE1; PHASE2
NCT04779957 COMPLETED Drug: Tocilizumab Kidney Transplantation; Graft Failure University Hospital, Toulouse 2021-10-01 PHASE2
NCT03380377 COMPLETED Drug: Clazakizumab Antibody-mediated Rejection; Kidney Transplant; Complications; Transplant Glomerulopathy; Transplant Glomerulopathy - Late Form; Transplant Glomerulopathy - Early Form; Kidney Transplant Rejection Stanley Jordan, MD 2018-02-21 PHASE1; PHASE2
NCT04876534 UNKNOWN Drug: Tocilizumab 20 Mg/mL Intravenous Solution|Drug: Methyl Graves Ophthalmopathy Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 2019-12-18 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-02-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.